Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.
Authors
- Gustavo Girotto (ORCID: https://orcid.org/0000-0002-4098-1320)
- Stefania Pipitone (ORCID: https://orcid.org/0000-0003-2677-1877)
- Gebski
- Linda Mileshkin
- Ingrid Boere
- Maria Pilar Barretina-Ginesta
- Dave Carter
- Koji Matsumoto
- Richard T. Penson
- Tomasz Huzarski
- Elizabeth S. Lowe
- Ignace Vergote
- Eric Pujade-Lauraine
- Ilan Bruchim
- Olga Mikheeva
- Tjoung-Won Park-Simon
- Alain Lortholary
- Jonathan A. Ledermann
- Nicoletta Colombo
- Rebecca Asher
- Jae-Weon Kim
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Modena and Reggio Emilia (IT)
- The University of Sydney (AU)
- Harvard University (US)
- Seoul National University (KR)
- Mercy Hospital for Women (AU)
- Hillel Yaffe Medical Center (IL)
- Erasmus MC (NL)
- Medizinische Hochschule Hannover (DE)
- Leningrad Regional Cancer Center (RU)
- Institut d'Investigació Biomèdica de Girona (ES)
- Hôpital privé du Confluent (FR)
- Fundação Faculdade de Medicina (BR)
- Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie (FR)
- AstraZeneca (United States) (US)
- Hyogo Prefectural Cancer Center (JP)
- National Health and Medical Research Council (AU)
- University College London (GB)
- University of Milano-Bicocca (IT)
- Université de Montréal (CA)
- Pomeranian Medical University (PL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1016/j.ijgc.2026.104556
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00